Hylton V. Joffe

2.9k total citations
32 papers, 1.3k citations indexed

About

Hylton V. Joffe is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Internal Medicine. According to data from OpenAlex, Hylton V. Joffe has authored 32 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Surgery and 7 papers in Internal Medicine. Recurrent topics in Hylton V. Joffe's work include Venous Thromboembolism Diagnosis and Management (7 papers), Hormonal and reproductive studies (5 papers) and Diagnosis and Treatment of Venous Diseases (4 papers). Hylton V. Joffe is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (7 papers), Hormonal and reproductive studies (5 papers) and Diagnosis and Treatment of Venous Diseases (4 papers). Hylton V. Joffe collaborates with scholars based in United States, Thailand and Canada. Hylton V. Joffe's co-authors include Samuel Z. Goldhaber, Nils Kucher, Victor F. Tapson, Gail K. Adler, Christine Nguyen, Mark Hirsch, David Moeny, F. Bradley Johnson, Ruliang Xu and Janina A. Longtine and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Hylton V. Joffe

27 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hylton V. Joffe United States 16 494 431 313 287 279 32 1.3k
Jean R. Cusson Canada 18 834 1.7× 156 0.4× 590 1.9× 172 0.6× 1.1k 3.8× 42 1.9k
Robert J. Glynn United States 9 451 0.9× 149 0.3× 317 1.0× 45 0.2× 668 2.4× 10 1.4k
Éric Pautas France 20 440 0.9× 90 0.2× 187 0.6× 56 0.2× 522 1.9× 80 1.4k
Giovanni B. Ambrosio Italy 20 149 0.3× 225 0.5× 221 0.7× 32 0.1× 762 2.7× 36 1.3k
A S Douglas United Kingdom 19 352 0.7× 101 0.2× 175 0.6× 31 0.1× 215 0.8× 56 1.2k
Li Fan China 22 38 0.1× 297 0.7× 231 0.7× 42 0.1× 635 2.3× 120 2.0k
Heather Halls Australia 8 180 0.4× 45 0.1× 428 1.4× 39 0.1× 460 1.6× 13 1.6k
Moshe Vardi Israel 14 98 0.2× 150 0.3× 189 0.6× 24 0.1× 143 0.5× 34 811
John A. McClung United States 27 72 0.1× 114 0.3× 395 1.3× 29 0.1× 679 2.4× 71 1.8k
Jung‐Im Shin United States 19 38 0.1× 385 0.9× 154 0.5× 69 0.2× 285 1.0× 70 1.1k

Countries citing papers authored by Hylton V. Joffe

Since Specialization
Citations

This map shows the geographic impact of Hylton V. Joffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hylton V. Joffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hylton V. Joffe more than expected).

Fields of papers citing papers by Hylton V. Joffe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hylton V. Joffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hylton V. Joffe. The network helps show where Hylton V. Joffe may publish in the future.

Co-authorship network of co-authors of Hylton V. Joffe

This figure shows the co-authorship network connecting the top 25 collaborators of Hylton V. Joffe. A scholar is included among the top collaborators of Hylton V. Joffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hylton V. Joffe. Hylton V. Joffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suzuki, Mari, Linda Jo Bone Jeng, Yan Wang, et al.. (2022). FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. Genetics in Medicine. 25(2). 100335–100335. 20 indexed citations
2.
Nguyen, Christine, et al.. (2017). FDA Regulation of Prescription Drugs. New England Journal of Medicine. 376(7). 674–682. 34 indexed citations
3.
Nguyen, Christine, et al.. (2015). Testosterone and “Age-Related Hypogonadism” — FDA Concerns. New England Journal of Medicine. 373(8). 689–691. 138 indexed citations
4.
Joffe, Hylton V., Christina Y. Chang, Catherine Sewell, et al.. (2015). FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder. New England Journal of Medicine. 374(2). 101–104. 72 indexed citations
5.
Li, Li, et al.. (2014). FDA Approval of Paroxetine for Menopausal Hot Flushes. New England Journal of Medicine. 370(19). 1777–1779. 54 indexed citations
6.
Joffe, Hylton V., et al.. (2014). FDA Approval of Doxylamine–Pyridoxine Therapy for Use in Pregnancy. New England Journal of Medicine. 370(12). 1081–1083. 31 indexed citations
7.
Fireman, Bruce, Sengwee Toh, Melissa G. Butler, et al.. (2012). A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiology and Drug Safety. 21(S1). 282–290. 34 indexed citations
8.
Joffe, Hylton V., et al.. (2010). Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. Reviews in Endocrine and Metabolic Disorders. 11(1). 21–30. 15 indexed citations
9.
10.
Dimitrakov, Jordan D., Hylton V. Joffe, Steven J. Soldin, et al.. (2008). Adrenocortical Hormone Abnormalities in Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Urology. 71(2). 261–266. 51 indexed citations
11.
Arreaza-Rubín, Guillermo, William Heetderks, Ilan Irony, et al.. (2007). FDA's proactive role in the development of an artificial pancreas for the treatment of diabetes mellitus. Drug Discovery Today Technologies. 4(1). 25–28. 5 indexed citations
12.
Joffe, Hylton V., et al.. (2007). Beneficial Effects of EplerenoneVersusHydrochlorothiazide on Coronary Circulatory Function in Patients with Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism. 92(7). 2552–2558. 69 indexed citations
13.
Joffe, Hylton V., Paul M. Ridker, JoAnn E. Manson, et al.. (2005). Sex Hormone-Binding Globulin and Serum Testosterone are Inversely Associated with C-Reactive Protein Levels in Postmenopausal Women at High Risk for Cardiovascular Disease. Annals of Epidemiology. 16(2). 105–112. 56 indexed citations
14.
Joffe, Hylton V. & Gail K. Adler. (2005). Effect of Aldosterone and Mineralocorticoid Receptor Blockade on Vascular Inflammation. Heart Failure Reviews. 10(1). 31–37. 84 indexed citations
15.
Joffe, Hylton V., Nils Kucher, Victor F. Tapson, & Samuel Z. Goldhaber. (2005). Few predictors of massive deep vein thrombosis. Thrombosis and Haemostasis. 94(11). 986–990. 1 indexed citations
16.
Joffe, Hylton V., Nils Kucher, & Victor F. Tapson. (2005). Upper-extremity deep vein thrombosis: A prospective registry of 592 patients. Journal of Vascular Surgery. 41(2). 371–371. 22 indexed citations
17.
Joffe, Hylton V., Nils Kucher, Victor F. Tapson, & Samuel Z. Goldhaber. (2004). 858-1 Risk factors for and inadequate prophylaxis against upper extremity deep vein thrombosis. Journal of the American College of Cardiology. 43(5). A524–A524. 1 indexed citations
18.
Joffe, Hylton V., Nils Kucher, Victor F. Tapson, & Samuel Z. Goldhaber. (2004). Upper-Extremity Deep Vein Thrombosis. Circulation. 110(12). 1605–1611. 256 indexed citations
19.
Johnson, F. Bradley, Janina A. Longtine, Nils Kucher, et al.. (2004). Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thrombosis and Haemostasis. 91(6). 1123–1128. 77 indexed citations
20.
Joffe, Hylton V. & Samuel Z. Goldhaber. (2002). Effectiveness and safety of long-term anticoagulation of patients ≥90 years of age with atrial fibrillation. The American Journal of Cardiology. 90(12). 1397–1398. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean R. Cusson Breakdown of academic impact, for papers by Robert J. Glynn Breakdown of academic impact, for papers by Éric Pautas Breakdown of academic impact, for papers by Giovanni B. Ambrosio Breakdown of academic impact, for papers by A S Douglas Breakdown of academic impact, for papers by Li Fan Breakdown of academic impact, for papers by Heather Halls Breakdown of academic impact, for papers by Moshe Vardi Breakdown of academic impact, for papers by John A. McClung Breakdown of academic impact, for papers by Jung‐Im Shin
Rankless by CCL
2026